PALBOCICLIB (Ibrance) prior authorization at Molina Healthcare
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Molina Healthcare requires Kinase Inhibitor prior-authorization documentation for PALBOCICLIB (Ibrance): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Molina Healthcare reviews PALBOCICLIB (Ibrance) prior authorizations against its medical policy for Kinase Inhibitor. Molina Healthcare-specific context: Primary Medicaid MCO + ACA Marketplace in 21 states. 42 CFR Part 438 Subpart F applies. State Fair Hearing is the escalation path after internal MCO appeal.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Kinase Inhibitor
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Molina Healthcare's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Medicaid MCO carve-outs
- Step therapy
- Specialty pharmacy denials
PALBOCICLIB (Ibrance)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring endocrine monotherapy first
- Combination partner not formulary (specific AI denied)
- Continuation beyond progression denied
- Specialty pharmacy network restriction
Brand: Ibrance. CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer. First-in-class. PALOMA trial series. Loss of exclusivity expected ~2027.
Manufacturer patient-assistance program: Pfizer Oncology Together — relevant when a Molina Healthcare denial sticks and the patient needs bridge access while appealing.
How Molina Healthcare approaches Specialty pharmacy drugs PAs
For PALBOCICLIB (IBRANCE), check whether the current Molina Healthcare Specialty pharmacy drugs policy cites step therapy or specialty pharmacy denials. Pharmacy-benefit review for PALBOCICLIB (IBRANCE) at Molina Healthcare is routed through state-specific Medicaid carve-in PBMs (varies by state Medicaid contract). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Molina Healthcare; if denied, use the filing date and route printed on that denial notice. Molina Healthcare routes specialty-pharmacy denials through a separate appeal queue from medical-benefit denials — verify the appeal goes to the correct queue or it can be administratively denied for "wrong path". Molina Healthcare is domiciled in CA, so unresolved appeals escalate to the CA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.molinahealthcare.com/providers) with the same packet plus an applicable, current clinical source supporting PALBOCICLIB (Ibrance)for the patient's indication.
Medicare Advantage cases may have plan reconsideration and independent-review steps. Confirm the current level, forwarding rule, and any expedited pathway directly in the notice before selecting an escalation route.
Molina Healthcare Medicare Advantage organization determinations operate under 42 CFR Part 422 Subpart D. For PALBOCICLIB (IBRANCE), the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. The applicable decision period and any Independent Review Entity routing depend on the request type, current rule, and plan notice. Record the cited source and version, then verify the operational due date against the current notice and CMS materials before relying on it.
Contact Molina Healthcare
- Provider portal: https://www.molinahealthcare.com/providers
Frequently asked questions
What documentation does Molina Healthcare need for PALBOCICLIB (Ibrance) prior auth?
Molina Healthcare's typical PA packet for PALBOCICLIB (Ibrance): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Kinase Inhibitor, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Molina Healthcare?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for PALBOCICLIB (Ibrance) at Molina Healthcare?
Preparation scenarios to check against the current notice and policy include: Medicaid MCO carve-outs; Step therapy; Specialty pharmacy denials. These are not measured frequency claims. For PALBOCICLIB (Ibrance), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Which specialty pharmacy will Molina Healthcare require for PALBOCICLIB (IBRANCE)?
Molina Healthcare contracts with a specific specialty-pharmacy network — using an out-of-network specialty pharmacy is a common denial cause that is administrative rather than medical-necessity. Call the prior-auth line on the back of the member card to confirm the in-network specialty pharmacy for PALBOCICLIB (IBRANCE) before submission. Note that REMS-restricted PALBOCICLIB (IBRANCE) variants (where applicable) further narrow the in-network pharmacy list. Pharmacy-benefit handling is routed through state-specific Medicaid carve-in PBMs (varies by state Medicaid contract). External-review escalation for Molina Healthcare fully-insured policies sits with the CA insurance department.
How do I prep for a peer-to-peer with Molina Healthcare on PALBOCICLIB (Ibrance)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the PALBOCICLIB (Ibrance) PA packet
Open ApprovalHelp — generate a PALBOCICLIB (Ibrance) prior-auth packet tailored to Molina Healthcare's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com